indans

Summary

Summary: Aryl CYCLOPENTANES that are a reduced (protonated) form of INDENES.

Top Publications

  1. pmc Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study
    Gregory Feldman
    S Carolina Pharmaceutical Research, Spartanburg, SC, USA
    BMC Pulm Med 10:11. 2010
  2. ncbi Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison
    Donald A Mahler
    Section of Pulmonary and Critical Care Medicine, Dartmouth Medical School, Hanover, New Hampshire, USA
    Thorax 67:781-8. 2012
  3. ncbi Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium
    James F Donohue
    University of North Carolina, 4125 Bioinformatics Building, 130 Mason Farm Road, CB 7020, Chapel Hill, NC, USA
    Am J Respir Crit Care Med 182:155-62. 2010
  4. ncbi Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD
    Ronald Dahl
    Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark
    Thorax 65:473-9. 2010
  5. ncbi Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison
    O Kornmann
    Pulmonary Division, Internal Medicine, University Hospital, Mainz, Germany
    Eur Respir J 37:273-9. 2011
  6. ncbi Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD
    R Buhl
    Pulmonary Department, Mainz University Hospital, Langenbeckstrasse 1, Mainz, D 55131, Germany
    Eur Respir J 38:797-803. 2011
  7. pmc Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis
    Shannon Cope
    Mapi Consultancy, Boston, MA, USA
    BMC Pulm Med 12:29. 2012
  8. ncbi Comparison of indacaterol with tiotropium or twice-daily long-acting β -agonists for stable COPD: a systematic review
    Gustavo J Rodrigo
    Departamento de Emergencia, Hospital Central de las Fuerzas Armadas, Montevideo, 11300 Uruguay
    Chest 142:1104-10. 2012
  9. ncbi Effect of indacaterol on exercise endurance and lung hyperinflation in COPD
    Denis E O'Donnell
    Queen s University and Kingston General Hospital, Kingston, Ontario K7L 2V7, Canada
    Respir Med 105:1030-6. 2011
  10. ncbi Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study
    Kenneth R Chapman
    Asthma and Airway Centre, University Health Network, Toronto Western Hospital, Toronto, ON, Canada
    Chest 140:68-75. 2011

Research Grants

Detail Information

Publications265 found, 100 shown here

  1. pmc Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study
    Gregory Feldman
    S Carolina Pharmaceutical Research, Spartanburg, SC, USA
    BMC Pulm Med 10:11. 2010
    ..This 12-week, double-blind study compared the efficacy, safety, and tolerability of indacaterol to that of placebo in patients with moderate-to-severe COPD...
  2. ncbi Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison
    Donald A Mahler
    Section of Pulmonary and Critical Care Medicine, Dartmouth Medical School, Hanover, New Hampshire, USA
    Thorax 67:781-8. 2012
    ..The authors investigated the approach of dual bronchodilation using indacaterol, a once-daily long-acting β(2) agonist, and the long-acting muscarinic antagonist tiotropium, compared with tiotropium alone...
  3. ncbi Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium
    James F Donohue
    University of North Carolina, 4125 Bioinformatics Building, 130 Mason Farm Road, CB 7020, Chapel Hill, NC, USA
    Am J Respir Crit Care Med 182:155-62. 2010
    ..Indacaterol is the first once-daily, long-acting inhaled beta(2)-agonist bronchodilator studied in patients with chronic obstructive pulmonary disease (COPD)...
  4. ncbi Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD
    Ronald Dahl
    Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark
    Thorax 65:473-9. 2010
    ..In previous studies, indacaterol provided 24 h bronchodilation on once-daily dosing with a fast onset of action. This study compared the efficacy and safety of indacaterol with the twice-daily LABA formoterol and placebo over 1 year...
  5. ncbi Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison
    O Kornmann
    Pulmonary Division, Internal Medicine, University Hospital, Mainz, Germany
    Eur Respir J 37:273-9. 2011
    ..Indacaterol should prove a useful additional treatment for patients with COPD...
  6. ncbi Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD
    R Buhl
    Pulmonary Department, Mainz University Hospital, Langenbeckstrasse 1, Mainz, D 55131, Germany
    Eur Respir J 38:797-803. 2011
    ..Both bronchodilators demonstrated spirometric efficacy. The two treatments were well tolerated with similar adverse event profiles. Compared with tiotropium, indacaterol provided significantly greater improvements in clinical outcomes...
  7. pmc Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis
    Shannon Cope
    Mapi Consultancy, Boston, MA, USA
    BMC Pulm Med 12:29. 2012
    ....
  8. ncbi Comparison of indacaterol with tiotropium or twice-daily long-acting β -agonists for stable COPD: a systematic review
    Gustavo J Rodrigo
    Departamento de Emergencia, Hospital Central de las Fuerzas Armadas, Montevideo, 11300 Uruguay
    Chest 142:1104-10. 2012
    ..Bronchodilators are central to the symptomatic management of patients with COPD.Previous data have shown that inhaled indacaterol improved numerous clinical outcomes over placebo...
  9. ncbi Effect of indacaterol on exercise endurance and lung hyperinflation in COPD
    Denis E O'Donnell
    Queen s University and Kingston General Hospital, Kingston, Ontario K7L 2V7, Canada
    Respir Med 105:1030-6. 2011
    ..This study investigated the effect of indacaterol on exercise endurance, and on lung hyperinflation during exercise and at rest in patients with moderate-to-severe COPD...
  10. ncbi Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study
    Kenneth R Chapman
    Asthma and Airway Centre, University Health Network, Toronto Western Hospital, Toronto, ON, Canada
    Chest 140:68-75. 2011
    ..Indacaterol is an inhaled, long-acting β(2)-agonist providing 24-h bronchodilation with once-daily dosing in patients with COPD...
  11. ncbi Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients
    R M Mroz
    Department of Lung Diseases, Medical University of Bialystok, Zurawia 14, Bialystok, Poland
    Adv Exp Med Biol 756:23-8. 2013
    ..The patients' quality of life also changed favorably in the indacaterol treatment arm. We conclude that the add-on therapy with indacaterol exerts positive effects in COPD patients...
  12. ncbi Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies
    Edward M Kerwin
    Clinical Research Institute of Southern Oregon PC, Medford, Oregon 97504, USA
    Clin Ther 33:1974-84. 2011
    ....
  13. ncbi QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease
    Jan A van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Heerlen, The Netherlands
    Thorax 65:1086-91. 2010
    ....
  14. ncbi Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study
    Stephanie Korn
    Pulmonary Department, Mainz University Hospital, Mainz, Germany
    Respir Med 105:719-26. 2011
    ..Indacaterol is a novel, inhaled once-daily ultra-long-acting β(2)-agonist for the treatment of COPD...
  15. pmc Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches
    Didier Renard
    Novartis Pharma AG, Basel, Switzerland
    Respir Res 12:54. 2011
    ..We considered alternative methods of analysis...
  16. pmc Safety of indacaterol in the treatment of patients with COPD
    James F Donohue
    University of North Carolina, Chapel Hill, NC 27599, USA
    Int J Chron Obstruct Pulmon Dis 6:477-92. 2011
    ..Pooled data were analyzed to evaluate the safety and tolerability of indacaterol, a once-daily inhaled long-acting β(2)-agonist for chronic obstructive pulmonary disease (COPD)...
  17. ncbi Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonist
    Diane M Ignar
    Metabolic Diseases Department, GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    J Pharmacol Exp Ther 339:24-34. 2011
    ..In conclusion, GSK1521498 is a potent, MOR-selective inverse agonist that modulates the hedonic aspects of ingestion and, therefore, could represent a pharmacological treatment for obesity and binge-eating disorders...
  18. ncbi Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison
    Shannon Cope
    Mapi Consultancy, Boston, MA 02114, USA
    Value Health 15:524-33. 2012
    ..Indacaterol trial evidence was synthesized to provide coherent estimates of indacaterol 150 μg and indacaterol 300 μg relative to formoterol, salmeterol, and tiotropium...
  19. pmc Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans
    E A Rabiner
    GSK Clinical Imaging Centre, Imperial College London, Hammersmith Hospital, London, UK
    Mol Psychiatry 16:826-35, 785. 2011
    ..Pharmacological differentiation of these molecules suggests that they may have different therapeutic profiles for treatment of overeating and other disorders of compulsive consumption...
  20. pmc Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eating
    Chiara Giuliano
    Behavioral and Clinical Neuroscience Institute and Department of Experimental Psychology, University of Cambridge, Cambridge, UK
    Neuropsychopharmacology 37:2643-52. 2012
    ....
  21. ncbi Indacaterol once-daily is equally effective dosed in the evening or morning in COPD
    H Magnussen
    Pulmonary Research Institute, Hospital Grosshansdorf, Grosshansdorf, Germany
    Respir Med 104:1869-76. 2010
    ..05); and the % of days able to perform usual activities (by 6.7 and 7.8 points; p < 0.05). Indacaterol provided 24-h bronchodilation and improvement in symptoms regardless of whether taken regularly in the morning or evening...
  22. pmc Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis
    Paul W Jones
    Division of Clinical Science, St George s, University of London, London, UK
    Respir Res 12:161. 2011
    ..We examined whether changes in trough forced expiratory volume in 1 second (FEV(1)) are correlated with changes in patient-reported outcomes...
  23. ncbi Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study
    Masaharu Kinoshita
    Nagata Hospital, Fukuoka, Japan
    Respirology 17:379-89. 2012
    ..This study was primarily designed to obtain the regulatory approval of indacaterol in Japan...
  24. ncbi Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium
    Andrea Rossi
    Unità Operativa Complessa di Pneumologia, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
    Respir Med 106:84-90. 2012
    ..Evidence has been provided that high-dose indacaterol (300 μg) can reduce lung hyperinflation in moderate-to-severe chronic obstructive pulmonary disease (COPD)...
  25. ncbi A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
    B Winblad
    Karolinska Institutet, Alzheimer s Disease Research Center, Division of Geriatric Medicine, Huddinge Hospital B, Stockholm, Sweden
    Neurology 57:489-95. 2001
    ..To evaluate the long-term clinical efficacy and safety of donepezil versus placebo over 1 year in patients with mild to moderate AD...
  26. pmc Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
    Claus Vogelmeier
    Novartis Pharmaceuticals Inc, One Health Plaza, East Hanover, NJ 07936 1080, USA
    Respir Res 11:135. 2010
    ..This randomized, double-blind study compared the bronchodilator efficacy of indacaterol with that of placebo and tiotropium in patients with moderate-to-severe COPD...
  27. ncbi Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients
    Boudewijn Van de Maele
    AZ Sint Jan Brugge Oostende AV, Campus H Serruys, Oostende, Belgium
    COPD 7:418-27. 2010
    ..Once-daily QVA149 was well tolerated in COPD patients with a cardiovascular safety profile and overall adverse event rates similar to placebo...
  28. ncbi Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD
    Kai Michael Beeh
    insaf Respiratory Research Institute, D 65187 Wiesbaden, Germany
    COPD 8:340-5. 2011
    ..In conclusion, indacaterol 300 μg administered once-daily showed a clinically relevant increase in IC after 14 days of treatment, reflecting a reduction in dynamic hyperinflation...
  29. ncbi Donepezil, an acetylcholinesterase inhibitor against Alzheimer's dementia, promotes angiogenesis in an ischemic hindlimb model
    Yoshihiko Kakinuma
    Department of Cardiovascular Control, Kochi Medical School, Nankoku, Kochi 783 8505, Japan
    J Mol Cell Cardiol 48:680-93. 2010
    ..The present study concludes that donepezil can act as a therapeutic tool to accelerate angiogenesis in cardiovascular disease patients...
  30. ncbi Efficacy of indacaterol in the treatment of patients with COPD
    Paul W Jones
    Division of Clinical Sciences, St George s University of London, London, UK
    Prim Care Respir J 20:380-8. 2011
    ..The safety profile was similar to placebo. Once-daily indacaterol is an effective and beneficial maintenance bronchodilator treatment for patients with moderate-to-severe COPD...
  31. ncbi Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis
    J Wang
    Department of Respiratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
    J Clin Pharm Ther 37:204-11. 2012
    ..However, the evidence that long-acting beta-agonists alone can reduce the rate of COPD exacerbations is not conclusive. This meta-analysis was performed to evaluate their effect on the frequency of exacerbations...
  32. ncbi Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist
    Pradeep J Nathan
    Clinical Unit Cambridge, Cambridge, UK
    J Clin Pharmacol 52:464-74. 2012
    ..These findings provide encouraging data in support of the development of GSK1521498 for the treatment of disorders of maladaptive ingestive behavior or compulsive consumption...
  33. ncbi Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies
    Mark H Gotfried
    Pulmonary Associates PA, Phoenix, AZ 85006, USA
    COPD 9:629-36. 2012
    ..Treatment with indacaterol 75 μg may provide useful improvements in patient-reported outcomes in patients with moderate-to-severe COPD...
  34. ncbi Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD
    Heinrich Worth
    Medical Department I, Klinikum Fürth, Jakob Henle Str 1, D 90766 Fürth, Germany
    Respir Med 105:571-9. 2011
    ..As COPD patients commonly suffer cardio- and cerebrovascular (CCV) co-morbidities, our purpose was to establish the CCV safety profile of indacaterol, a novel, inhaled, long-acting β(2)-agonist for COPD...
  35. pmc Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol
    Gregory J Feldman
    S Carolina Pharmaceutical Research, Alliance Biomedical Group International, Spartanburg, SC 29303, USA
    Int J Chron Obstruct Pulmon Dis 8:89-96. 2013
    ..As there is no cure for COPD, a major goal of treatment and of research into new therapies is to improve HR-QOL in COPD patients...
  36. pmc Comparative efficacy of indacaterol in chronic obstructive pulmonary disease
    Marcos Ribeiro
    Asthma and Airway Centre, University Health Network, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
    Int J Chron Obstruct Pulmon Dis 7:145-52. 2012
    ..It is likely that once-daily dosing of a bronchodilator would be a significant convenience and probably a compliance-enhancing advantage, leading to improved overall clinical outcomes in patients with COPD...
  37. pmc Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone
    Beatrix Balint
    Csongrád Megyei OnkormányzatMellkasi Betegségek Szakkórháza, Deszk, Hungary
    Int J Chron Obstruct Pulmon Dis 5:311-8. 2010
    ..indacaterol is a novel, inhaled once-daily ultra-long-acting β(2)-agonist for the treatment of chronic obstructive pulmonary disease (COPD)...
  38. ncbi Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the μ-opioid receptor inverse agonist GSK1521498
    Pradeep J Nathan
    GlaxoSmithKline, Clinical Unit Cambridge, Addenbrooke s Hospital, Hills Road, Cambridge CB2 2GG UK
    J Clin Pharmacol 52:1456-67. 2012
    ..These findings provide encouraging safety, tolerability, and pharmacokinetic data in support of the continued clinical development of GSK1521498...
  39. pmc Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis
    Shannon Cope
    Mapi Consultancy, Boston, MA 02114, USA
    Int J Chron Obstruct Pulmon Dis 7:415-20. 2012
    ....
  40. pmc Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data
    Eugene R Bleecker
    Center for Genomics and Personalized Medicine Research and Translational Medicine Institute, Wake Forest University Health Sciences, Winston Salem, NC 27157, USA
    Int J Chron Obstruct Pulmon Dis 6:431-8. 2011
    ..As indacaterol is the first once-daily β(2)-agonist to be developed, it is relevant to evaluate its bronchodilator efficacy, safety, and tolerability...
  41. pmc Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD
    Kenneth R Chapman
    Asthma and Airway Centre, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
    Int J Chron Obstruct Pulmon Dis 6:353-63. 2011
    ..These are important factors for optimum dose delivery and successful COPD management...
  42. ncbi Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy
    David G Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Drugs Aging 21:453-78. 2004
    ....
  43. ncbi Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial
    Akira Homma
    Dementia Interventional Research Group, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
    Dement Geriatr Cogn Disord 25:399-407. 2008
    ..A 24-week, randomized, parallel-group, double-blind placebo-controlled study was conducted to evaluate the efficacy and tolerability of donepezil in severe Alzheimer's disease (AD)...
  44. ncbi Vitamin E and donepezil for the treatment of mild cognitive impairment
    Ronald C Petersen
    Mayo Clinic College of Medicine, Rochester, Minn, USA
    N Engl J Med 352:2379-88. 2005
    ..Mild cognitive impairment is a transitional state between the cognitive changes of normal aging and early Alzheimer's disease...
  45. pmc Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, 46202, USA
    Clin Ther 32:1234-51. 2010
    ..We hypothesized that the loss of initial therapeutic benefit over time may be mitigated by higher doses of a cholinesterase inhibitor...
  46. pmc Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis
    Shannon Cope
    Mapi Values, Boston, MA, USA
    Int J Chron Obstruct Pulmon Dis 6:329-44. 2011
    ....
  47. ncbi Anti-Alzheimer's drug, donepezil, markedly improves long-term survival after chronic heart failure in mice
    Takemi Handa
    Department of Cardiovascular Control, Kochi Medical School, Nankoku, Japan
    J Card Fail 15:805-11. 2009
    ....
  48. ncbi Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity
    Orly Weinreb
    Eve Topf Centre of Excellence for Neurodegenerative Diseases, Technion Rappaport Faculty of Medicine, Efron St PO Box 9697, Haifa 31096, Israel
    Prog Neurobiol 92:330-44. 2010
    ..This paper will review the earlier and present studies in the development of rasagiline for treatment of PD and discuss its pharmacology and applicable mechanism of action...
  49. ncbi Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment
    Carina Wattmo
    Department of Clinical Sciences, Clinical Memory Research Unit, Malmo, Lund University, Sweden
    Alzheimer Dis Assoc Disord 25:63-72. 2011
    ..AD severity at baseline is a key factor in obtaining reliable clinical prognoses of the long-term ADL ability. The dosage of ChEI treatment could possibly lead to a different functional outcome...
  50. ncbi Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review
    Dimitris Repantis
    Department of Psychiatry, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Eschenallee 3, 14050 Berlin, Germany
    Pharmacol Res 61:473-81. 2010
    ..At the moment, the research that would support or oppose the use of acetylcholinesterase inhibitors and memantine for neuroenhancement by healthy individuals has not yet been performed...
  51. ncbi Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design
    Peter J Barnes
    Imperial College, London, UK
    Pulm Pharmacol Ther 23:165-71. 2010
    ..This approach was used in a clinical study of indacaterol, a novel once-daily (od) inhaled long-acting beta(2)-adrenoreceptor agonist bronchodilator for the treatment of COPD (chronic obstructive pulmonary disease)...
  52. ncbi Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
    O Rascol
    Clinical Investigation Centre, Department of Clinical Pharmacology, University Hospital, Toulouse, France
    Lancet 365:947-54. 2005
    ..This study investigated rasagiline efficacy and safety in levodopa-treated patients with Parkinson's disease and motor fluctuations...
  53. ncbi Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study
    Aurelia Santoro
    Department of Experimental Pathology, University of Bologna, Via S Giacomo 12, Bologna, Italy
    CNS Drugs 24:163-76. 2010
    ..g. health status and co-morbidities) associated with a complex disease such as AD in elderly people...
  54. ncbi Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons
    Yuki Takada
    Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan
    J Pharmacol Exp Ther 306:772-7. 2003
    ..These results suggest that donepezil not only protects cortical neurons against glutamate neurotoxicity via alpha4beta2- and alpha7-nAChRs but also prevents apoptotic neuronal death...
  55. ncbi Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease
    Robert A Hauser
    Parkinsons s Disease and Movement Disorders Center, University of South Florida, 5 Tampa General Circle, Tampa, FL 33606, USA
    Mov Disord 24:564-73. 2009
    ..This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD...
  56. ncbi Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease
    R S Doody
    Department of Neurology, Baylor College of Medicine, 6550 Fannin Street, Suite 1801, Houston, TX 77030-3498, USA
    Arch Neurol 58:427-33. 2001
    ..CONCLUSIONS: Donepezil is an effective and safe drug for the long-term symptomatic treatment of mild to moderately severe AD for up to 144 weeks (2.8 years), and sustained treatment may confer some advantages...
  57. ncbi Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting
    Asa K Wallin
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden
    Dement Geriatr Cogn Disord 23:150-60. 2007
    ..Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer's disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated...
  58. pmc Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment
    Danielle C Whitehair
    Department of Neurosciences, University of California, San Diego, CA, USA
    Alzheimers Dement 6:412-9. 2010
    ..We examine the prospective association of APOE varepsilon4 allele status on measures of cognitive and functional decline in subjects with amnestic MCI (aMCI)...
  59. pmc Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease
    Charlotta Karner
    Population Health Sciences and Education, St George s, University of London, London, UK
    Cochrane Database Syst Rev 4:CD008989. 2012
    ..However, the benefits and risks of combining tiotropium and long-acting beta(2)-agonists for the treatment of chronic obstructive pulmonary (COPD) disease are unclear...
  60. ncbi Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD
    Paul W Jones
    Division of Clinical Science, St George s University of London, Cranmer Terrace, London SW17 0RE, UK
    Respir Med 105:892-9. 2011
    ..The aim of this paper is to assess the effect of indacaterol on dyspnoea and health status, using pooled study data to evaluate the relative efficacy of indacaterol and existing bronchodilators...
  61. ncbi Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine
    Rachelle S Doody
    Baylor College of Medicine, Houston, TX 07730, USA
    Dement Geriatr Cogn Disord 33:164-73. 2012
    ..We evaluated the efficacy/safety of donepezil 23 and 10 mg/day in this trial, with respect to concomitant memantine use...
  62. ncbi Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices
    Richard G Sturton
    Novartis Pharma AG, WSJ 386 12 16, P O Box, CH 4002 Basel, Switzerland
    J Pharmacol Exp Ther 324:270-5. 2008
    ..Finally, using the human lung slice model, we have characterized indacaterol as a fast acting compound with a longer duration of action than salmeterol and formoterol...
  63. ncbi Kinetic analysis of the inhibition of phenylalanine ammonia-lyase by 2-aminoindan-2-phosphonic acid and other phenylalanine analogues
    Christoph Appert
    Institute of Plant Sciences, Federal Institute of Technology Zurich, CH 8092 Zurich, Switzerland
    Phytochemistry 62:415-22. 2003
    ..The carboxyl analogue of AIP, 2-aminoindan-2-carboxylic acid, served as a substrate of PAL-1 and was converted to indene-2-carboxylic acid...
  64. ncbi Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease
    Kate McKeage
    Adis, Auckland, New Zealand
    Drugs 72:543-63. 2012
    ..In conclusion, indacaterol provides a valuable option for the maintenance treatment of adults with COPD...
  65. pmc Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol
    Jutta Beier
    insaf Respiratory Research Institute, Wiesbaden, Germany
    Int J Chron Obstruct Pulmon Dis 6:237-43. 2011
    ..This review summarizes relevant clinical data for twice-daily β-2-agonists in COPD, and further focuses on novel data for once-daily indacaterol, including head-to-head comparison trials...
  66. ncbi Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study
    Ronald Dahl
    Department of Clinical Medicine, Aarhus University, Aarhus, Denmark Electronic address
    Respir Med 107:1558-67. 2013
    ..We investigated the safety and efficacy of QVA149 over 52 weeks...
  67. ncbi Delirium caused by donepezil: a case study
    Toshiro Kawashima
    J Clin Psychiatry 63:250-1. 2002
  68. pmc DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT
    Rob Jones
    Section of Old Age Psychiatry, The University of Nottingham, A Floor, South Block, Queen s Medical Centre, Nottingham NG7 2UH, UK
    Trials 10:57. 2009
    ..The aim of this trial is to establish the most effective drug option for people with AD who are progressing from moderate to severe dementia despite treatment with donepezil...
  69. ncbi Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil
    Hind T Hatoum
    Center for Pharmacoeconomic Research, the University of Illinois at Chicago UIC, Chicago, IL, USA
    J Med Econ 12:98-103. 2009
    ..To quantify the impact of activities of daily living (ADL) scores on the risk of nursing home placement (NHP) in Alzheimer's disease (AD) patients...
  70. ncbi Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications
    F Fagnani
    CEMKA, Bourg la Reine, France
    Dement Geriatr Cogn Disord 17:5-13. 2004
    ..Overall, these data suggest that donepezil is a cost-effective treatment for mild to moderately impaired AD patients living in France...
  71. ncbi A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Curr Med Res Opin 26:263-9. 2010
    ..To investigate the tolerability and efficacy of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease receiving concomitant memantine...
  72. ncbi Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice
    Hiroyuki Umegaki
    Department of Geriatrics, Nagoya University Graduate School of Medicine, Aichi, Japan
    Int Psychogeriatr 20:800-6. 2008
    ..In the current study we surveyed the discontinuation of donepezil, a cholinesterase inhibitor, for the treatment of Alzheimer's disease in a Japanese geriatric outpatient clinic in a university hospital...
  73. ncbi Cholinoceptive and cholinergic properties of cardiomyocytes involving an amplification mechanism for vagal efferent effects in sparsely innervated ventricular myocardium
    Yoshihiko Kakinuma
    Department of Cardiovascular Control, Kochi Medical School, Nankoku, Japan
    FEBS J 276:5111-25. 2009
    ..Such an amplification system in cardiomyocytes may contribute to the beneficial effects of vagal stimulation on the ventricles...
  74. pmc Cholinergic enhancement reduces spatial spread of visual responses in human early visual cortex
    Michael A Silver
    School of Optometry, University of California, Berkeley, Berkeley, CA 94720, USA
    Neuron 60:904-14. 2008
    ..These findings demonstrate that acetylcholine regulates spatial integration in human visual cortex...
  75. ncbi A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease
    Norman R Relkin
    Department of Neurology and Neuroscience, Weill Medical College of Cornell University, 428 East 72nd Street, Suite 500, New York, N Y 10021, USA
    Dement Geriatr Cogn Disord 16:15-24. 2003
    ..These results highlight donepezil as a safe and effective treatment for AD patients typically seen by community-based physicians...
  76. ncbi Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study
    Mercè Boada-Rovira
    Fundacio ACE, Barcelona, Spain
    Drugs Aging 21:43-53. 2004
    ..However, in order to control for confounding factors, some clinical trials of donepezil have excluded patients with comorbid illness and concomitant medication use...
  77. ncbi Indacaterol therapy in patients with COPD not receiving other maintenance treatment
    Marc Decramer
    Respiratory Division, University Hospitals, Chief Respiratory Division UZ Leuven, Campus Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Respir Med 106:1706-14. 2012
    ..Recent findings of rapid lung function decline in younger patients with moderate COPD severity suggest the need for effective early treatment...
  78. ncbi Donepezil preserves cognition and global function in patients with severe Alzheimer disease
    S E Black
    Division of Neurology, Department of Medicine and Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada
    Neurology 69:459-69. 2007
    ..To evaluate the efficacy and safety of donepezil for severe Alzheimer disease (AD)...
  79. pmc Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology
    Marwan Sabbagh
    The Cleo Roberts Center for Clinical Research, Banner Sun Health Research Institute, Sun City, Arizona, USA
    BMC Neurol 11:21. 2011
    ....
  80. ncbi Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats
    S Eliash
    Department of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Israel
    J Neural Transm 108:909-23. 2001
    ..The drugs were equipotent when they were given at a ratio of 1:2. The mechanism has yet to be elucidated. The differential effects of the drugs on blood pressure and MAO inhibition rule out either effect as the sole explanation...
  81. ncbi Investigation into the efficacy of the acetylcholinesterase inhibitor, donepezil, and novel procognitive agents to induce gamma oscillations in rat hippocampal slices
    J P Spencer
    Synaptic Plasticity and Neural Network Dynamics Discovery Performance Unit, Neurosciences CEDD, GlaxoSmithKline, New Frontiers Science Park, Harlow, Essex, CM19 5AW, UK
    Neuropharmacology 59:437-43. 2010
    ..These data support the notion that it should be possible to find a more efficacious AChE inhibitor or an adjunctive approach, to provide a better therapeutic intervention in AD...
  82. ncbi An update on the use of indacaterol in patients with COPD
    Nadia S Brienza
    Respiratory Research Unit, Complexo Hospitalario Universitario and Instituto de Investigación Biomédica de A Coruña INIBIC, Spain
    Ther Adv Respir Dis 5:29-40. 2011
    ....
  83. ncbi The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease
    Sarah Thompson
    Sunnybrook and Women s College Health Sciences Centre, Department of Psychiatry, Rm FG 05, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada
    Expert Opin Drug Saf 3:425-40. 2004
    ..Further study is needed to examine other indications for ChEIs, as well as their combination with newer treatments, such as memantine...
  84. ncbi Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failure
    Yoshihisa Okazaki
    Department of Artificial Organ Medicine, Division of Surgical Medicine, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
    J Physiol Sci 60:67-74. 2010
    ..These findings indicated that donepezil reproduced the anti-remodeling effect of electrical vagal stimulation. Further studies are warranted to evaluate the clinical usefulness of donepezil in heart failure...
  85. ncbi Effects of cognitive-communication stimulation for Alzheimer's disease patients treated with donepezil
    Sandra Bond Chapman
    The University of Texas at Dallas, USA
    J Speech Lang Hear Res 47:1149-63. 2004
    ..The fact that AD is a progressive brain disease should not preclude ameliorative treatment...
  86. ncbi Cognition and function in Alzheimer's disease: identifying the transitions from moderate to severe disease
    Elias Schwam
    Pfizer Global Pharmaceuticals, Pfizer Inc, New York, NY, USA schwae pfizer com
    Dement Geriatr Cogn Disord 29:309-16. 2010
    ....
  87. ncbi Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation
    Denis Getsios
    United BioSource Corporation, Lexington, MA02420, USA
    Pharmacoeconomics 28:411-27. 2010
    ..They also indicate that both benefits and savings may be greatest when treatment is started while patients are still in the mild stages of Alzheimer's disease...
  88. ncbi Dopamine D1 receptors synergize with D2, but not D3 or D4, receptors in the striatum without the involvement of action potentials
    G J LaHoste
    Department of Psychology, University of New Orleans, New Orleans, Louisiana 70148, USA
    J Neurosci 20:6666-71. 2000
    ....
  89. ncbi Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease
    F Blandini
    Laboratory of Functional Neurochemistry, Neurological Institute C Mondino, 27100, Pavia, Italy
    Exp Neurol 187:455-9. 2004
    ..Our study supports the neuroprotective potential of chronic rasagiline administration in an experimental model of Parkinson's disease (PD)...
  90. ncbi Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan
    Motohiro Nozawa
    Department of Psychiatry, Juntendo Tokyo Koto Geriatric Medial Center, Juntendo University School of Medicine, Tokyo, Japan
    Psychogeriatrics 9:50-5. 2009
    ..Donepezil 10 mg/day gained approval in Japan in August 2007 for the treatment of cognitive dysfunction in advanced Alzheimer's disease...
  91. ncbi Down-regulation of metabotropic glutamate receptor 1alpha in globus pallidus and substantia nigra of parkinsonian monkeys
    K Kaneda
    Department of System Neuroscience, Tokyo Metropolitan Institute for Neuroscience, Tokyo Metropolitan Organization for Medical Research, Fuchu, Tokyo 183 8526, Japan
    Eur J Neurosci 22:3241-54. 2005
    ....
  92. ncbi A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease
    Gordon Wilcock
    Department of Care of the Elderly, University of Bristol, Frenchay Hospital, Bristol, UK
    Drugs Aging 20:777-89. 2003
    ..To compare the long-term efficacy and safety of galantamine 24 mg/day and donepezil 10 mg/day in patients with Alzheimer's disease...
  93. ncbi Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: lessons learned
    Sarah Lyle
    Services for Older People, Shelton Hospital, Shrewsbury, UK
    Dement Geriatr Cogn Disord 25:226-31. 2008
    ..In the UK it is recommended that acetylcholinesterase inhibitors be restricted to patients with moderate Alzheimer's disease, and progress monitored within specialist clinics...
  94. ncbi Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model
    Stefan Waibel
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany
    J Neurol 251:1080-4. 2004
    ..Therefore, we conclude that the combination of rasagiline and riluzole is a promising clinical combination for the improvement of current neuroprotective treatment strategies of ALS...
  95. ncbi Effects of the long-acting monoamine reuptake inhibitor indatraline on cocaine self-administration in rhesus monkeys
    S S Negus
    Alcohol and Drug Abuse Research Center, Harvard Medical School McLean Hospital, Belmont, Massachusetts, USA
    J Pharmacol Exp Ther 291:60-9. 1999
    ..These findings suggest that although indatraline may decrease cocaine-taking behavior in rhesus monkeys, it also produces undesirable side effects that may limit its clinical utility in the treatment of cocaine dependence...
  96. ncbi Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi
    E Naline
    Research Unit EA220, Faculty of Medicine, Versailles University, Hospital Foch, Suresnes, France
    Eur Respir J 29:575-81. 2007
    ..3+/-8.8 and 14.6+/-3.7 min for formoterol and salbutamol, respectively. In isolated human bronchi, indacaterol behaved as a long-acting beta2-adrenoceptor agonist with high intrinsic efficacy and fast onset of action...
  97. ncbi Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease
    Rachelle S Doody
    Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Drugs Aging 25:163-74. 2008
    ..Higher doses of donepezil, if safe and well tolerated, might provide further benefits for patients with AD...
  98. ncbi Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters
    Han Yu
    Laboratory of Medicinal Chemistry, Building 8, Room B1 23, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, 20892 0815, USA
    J Med Chem 47:2624-34. 2004
    ..Ex vivo autoradiography, however, demonstrated that iv administration of (-)-(1R,3S)-11 produced a dose-dependent, persistent occupation of 5-HT transporter binding sites but not DA transporter sites...
  99. ncbi Mechanism of neuroprotection by donepezil pretreatment in rat cortical neurons chronically treated with donepezil
    Yuki Takada-Takatori
    Department of Pharmacology, Faculty of Pharmaceutical Sciences, Doshisha Women s College, Kyoto, Japan
    J Neurosci Res 86:3575-83. 2008
    ..This study provides novel insight into the mechanism of donepezil-induced neuroprotection that involves nAChR up-regulation...
  100. ncbi A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Mov Disord 23:2194-201. 2008
    ..We here describe the rationale for the study and baseline characteristics of the 1,176 patients who have been enrolled into the trial...
  101. ncbi Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD
    S Pascoe
    Novartis Pharma AG, Basel, Switzerland
    Int J Clin Pharmacol Ther 49:153-61. 2011
    ..The 24-h bronchodilator effect and pharmacokinetics of indacaterol were also investigated...

Research Grants67

  1. GHB: Discrimination and effects on learning
    Lisa Baker; Fiscal Year: 2003
    ..Behavior under these assays is sensitive to other abused drugs. Therefore, these assays may be of value in characterizing the effects of GHB. ..
  2. Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects
    Christopher H van Dyck; Fiscal Year: 2010
    ..This Pilot Clinical Trial will provide essential preliminary data for a subsequent full-scale trial of guanfacine for prefrontally-mediated cognitive dysfunction in elderly subjects. ..
  3. REGULATION OF SENESCENCE AND APOPTOSIS IN LYMPHOCYTES
    Dennis Carson; Fiscal Year: 2004
    ....
  4. DOUBLE-BLIND CONTROLLED TRIAL OF NIGRAL GRAFTING IN PD
    C Olanow; Fiscal Year: 2003
    ..abstract_text> ..
  5. Multiple Factors Affecting Placebo Response in PD
    Christopher Goetz; Fiscal Year: 2004
    ..Defining these determinant influences will help enhance placebo responses in clinical practice and control them in clinical trials. ..
  6. Depression in Alzheimer's Disease Study 2 (DIADS-2)
    Lon Schneider; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  7. Predictors of Alzheimers Disease in Mild Cognitive Impairment
    Oscar Lopez; Fiscal Year: 2007
    ..g., structural and perfusion MRI, plasma beta-amyloid) and the factors that modify the risk to express the clinical syndrome takes on an added importance. [unreadable] [unreadable] [unreadable] [unreadable]..
  8. Light Treatment for Sleep/Wake Disturbances AD
    Jerome Yesavage; Fiscal Year: 2008
    ..Outcome will be documented by objective circadian activity rhythm parameters and standard sleep/wake measures both assessed by actigraphy. ..
  9. TREATMENTS FOR INSOMNIA
    Jerome Yesavage; Fiscal Year: 2003
    ..This five-year application will ultimately include 90 treatment subjects aged >60 years (three groups of 30 each). ..
  10. A Comprehensive Database of Cost-Effectiveness Analyses
    Peter Neumann; Fiscal Year: 2003
    ..The web-based data should also understand the needs of different scientists to be understood and policymakers, and bridges to be built across disparate communities. ..
  11. Substance Abuse in ADHD Girls
    Timothy Wilens; Fiscal Year: 2006
    ..Thus, the research, approach, and goals of this R01 application are consistent with those underscored in the PA and by the Institute of Medicine as being of the highest research priority. ..
  12. CDP-choline: Mechanisms in Cerebral Ischemia
    RAO ADIBHATLA; Fiscal Year: 2006
    ..Arachidonic acid activates neutral sphingomyelinase, resulting in membrane disintegration. PCCT activity was stimulated by exogenous CDP-choline. Aim 2 will be tested in gerbil transient forebrain ischemia. ..
  13. AD CAREGIVER WELL-BEING COUNSELING/INSTITUTIONALIZATION
    Mary Mittelman; Fiscal Year: 2006
    ..abstract_text> ..
  14. Southeastern Michigan Parkinson's Disease Program
    Peter LeWitt; Fiscal Year: 2006
    ..This application also discusses concepts for three pharmacological agents that could be investigated in pilot studies and, if promising, in multicenter clinical trials for assessing neuroprotection. ..
  15. MEDICAL GOALS IN DEMENTIA: ETHICS & QUALITY OF LIFE
    Peter Whitehouse; Fiscal Year: 2005
    ..In the final years of the proposal we will develop interventions based on the knowledge accumulated during the initial periods of the grant to enhance the decision- making of other caregiving units. ..
  16. Alzheimer's Disease Research Center Conference
    Leon Thal; Fiscal Year: 2006
    ..Partial support is requested to defray travel costs of invited speakers and to provide travel awards to minority healthcare providers, junior faculty, postdocs and students. [unreadable] [unreadable] [unreadable]..
  17. SOCIAL FACTORS AND EPIDEMIOLOGY OF COGNITIVE DECLINE
    Marie Florence Shadlen; Fiscal Year: 2005
    ..Hence, these projects will allow Dr Shadlen to achieve her 5-year goal of synthesis of her interests in racial differences, dementia, and epidemiology into an independent, thought-provoking research program. ..
  18. Safety and Efficacy of Sertraline for Depression Congestive Heart Failure
    Ranga Krishnan; Fiscal Year: 2007
    ..Information collected in these follow-up contacts will include deaths, re-hospitalizations, cardiac events, functional status/quality of life measures, and level of depressive symptoms. ..
  19. Creation and demonstration of a palliative care research cooperative group
    Jean S Kutner; Fiscal Year: 2010
    ....
  20. Effects of Chemotherapy on Brain Function
    William J Jagust; Fiscal Year: 2010
    ..They are also relevant to the overall mission of the NIH because of the negative impact that cognitive dysfunction has on quality of life. ..
  21. Study on Thalidomide as BACE1 inhibitor in Alzhiemer's disease
    Marwan N Sabbagh; Fiscal Year: 2010
    ..We propose that Thalidomide may represent a BACE1 inhibitor. ..
  22. Parenteral Hydration in Advanced Cancer Patients: A Randomized Controlled Trial
    Eduardo Bruera; Fiscal Year: 2009
    ..In this study, we will test if giving fluid through the vein will improve the symptoms, delay confusion and prolong life in patients who are no longer to drink at the end of life. ..
  23. Juvenile Bipolar Disorder and Substance Abuse
    Timothy E Wilens; Fiscal Year: 2010
    ..Since BPD is identifiable and treatable, findings from the four-year follow-up will provide valuable information to formulate prevention and early intervention strategies. ..
  24. Siblings With Ischemic Stroke Study (SWISS)
    JAMES MESCHIA; Fiscal Year: 2009
    ..DNA banking and the creation of permanent lymphoblastoid cell lines will be done to permit future collaborative efforts to study the genetic basis for stroke risk. ..
  25. Glycine Transport Inhibition for Nicotine Dependence in Schizophrenia
    A Evins; Fiscal Year: 2009
    ....
  26. Amyloid Imaging in Frontotemporal Dementia and Alzheimer's Disease
    William Jagust; Fiscal Year: 2009
    ..PIB could become a diagnostic tool that is useful in diagnosing AD and FTLD during life. This will be especially important as new treatments for both disorders are developed. ..
  27. CNS Mechanisms that Modulate Reward
    KENNETH CARR; Fiscal Year: 2008
    ..The research proposed in this application is aimed at elucidating midbrain and striatal mechanisms involved in the increased behavioral responsiveness of FR rats to drugs of abuse. ..
  28. Donepezil-enhanced management of delirium in aged hip fracture patients
    Edward Marcantonio; Fiscal Year: 2007
    ..This study is the first in the PI's long-term goal to better understand the pathophysiological mechanisms of delirium and to develop and test therapies targeted to address these mechanisms. [unreadable] [unreadable] [unreadable]..
  29. DEMENTIA AND PSYCHIATRIC DISORDERS IN ASSISTED LIVING
    Adam Rosenblatt; Fiscal Year: 2007
    ..abstract_text> ..
  30. Treating Mildly Cognitive- Impaired Depressed Elderly
    Gregory Pelton; Fiscal Year: 2005
    ....
  31. Alzheimer's Disease in Down Syndrome: Antioxidant Trial
    Ira Lott; Fiscal Year: 2005
    ..The pilot trial should also contribute information as to the possible role of antioxidants in the treatment or prevention of AD in the general population. ..
  32. Treating Agitation/Psychosis in Dementia/Parkinsonism
    Roger Kurlan; Fiscal Year: 2004
    ..This study will provide important information regarding the optimal treatment of psychosis and agitation for patients with the commonly encountered combination of primary dementia and parkinsonism. ..
  33. POLYAMINE INVOLVEMENT IN MAMMARY CARCINOGENESIS
    Andrea Manni; Fiscal Year: 2001
    ....
  34. Third Symposium Cell Volume & Signalling Regulation
    PETER LAUF; Fiscal Year: 2003
    ..This meeting's success on U.S. soil will foster continuation of gathering of high-caliber scientists at subsequent international meetings ..
  35. Neuropeptide Y for Cancer-Associated Anorexia
    Aminah Jatoi; Fiscal Year: 2003
    ..These two pilot studies will allow us to lay the groundwork for such larger trials. Our ultimate goal is to help cancer patients who suffer from anorexia. ..
  36. Pioglitazone in Alzheimer's Disease Progression
    David Geldmacher; Fiscal Year: 2003
    ..Comparison of mean differences (using last observation carried forward imputation techniques) and survival analyses will be employed to assess for group differences in clinical measures AD of progression. ..
  37. Nocardia: A Novel Environmental Agent For Parkinsonism?
    Peter LeWitt; Fiscal Year: 2003
    ..These outcomes will be significant because they should add to our understanding of the neurodegenerative process in PD, and could lead to improved means of diagnosis and treatment for individuals with this disorder. ..
  38. CANCER RESEARCH TRAINING IN NUCLEAR MEDICINE
    David Kuhl; Fiscal Year: 2003
    ..The combination of faculty motivation, structured curricula, excellent facilities, and superb intellectual environment is expected to prepare individuals to be tomorrow's leaders in cancer research. ..
  39. DEPRESSION IN ELDERLY CARDIAC PATIENTS
    Ranga Krishnan; Fiscal Year: 2003
    ....
  40. PREVENTION OF SUICIDE IN OLDER PRIMARY CARE PATIENTS
    Charles Reynolds; Fiscal Year: 2002
    ..Data will also be collected to document the impact of intervention on patient care, and on physician knowledge, attitudes, and satisfaction and test hypothesis derived from preliminary studies of the three IRCs. ..
  41. FUNCTIONAL BRAIN IMAGING WITH RNA REDISTRIBUTION ANALYSI
    Carol Barnes; Fiscal Year: 2002
    ..Our long-term goal is to create a novel image analysis tool that links behavioral systems, and molecular neuroscience approaches to a variety of behaviors and brain regions. ..
  42. Mode of Action of Insecticides: Electrophysiological
    Toshio Narahashi; Fiscal Year: 2004
    ..This information will significantly contribute to the development of newer therapeutic means of insecticide intoxication of humans and of more effective and safer insecticides. ..
  43. LUNG HEALTH STUDY--LONG TERM FOLLOW UP
    Donald Tashkin; Fiscal Year: 2002
    ..All ten of the original LHS clinical centers plan to participate in this study. To minimize bias, all surviving participants of the LHS will be invited to participate, giving a potential sample size of 5600. ..
  44. Polyamines and Breast Cancer Biology
    Andrea Manni; Fiscal Year: 2005
    ..The ultimate goal of these studies is to identify critical signaling molecules which can be targeted in conjunction with antipolyamine therapy to optimize prevention of metastasis from breast cancer. ..
  45. Effects of Androgens and Cannabinoids on Learning
    STUART LEONARD; Fiscal Year: 2005
    ..These results will provide, for the first time, information regarding the interactive effects of testosterone and THC on cognitive behavior. ..
  46. CI Therapy and Novel Virtual Environments
    Carolee Winstein; Fiscal Year: 2005
    ..Phase II will establish a broader application in the clinical environment, incorporate patient perspectives, and longer-term outcomes. ..
  47. Treatment Outcomes of Vascular Depression
    PUDUGRAMAM DORAISWAMY; Fiscal Year: 2005
    ..The proposed trial will provide information of value to the practitioner and also provide data to build a more comprehensive model of the prognostic impact of frontal-subcortical brain changes on the outcome of late-life depression. ..
  48. GENE THERAPY OF BASAL FOREBRAIN CHOLINERGIC LESIONS
    Leon Thal; Fiscal Year: 2004
    ..These approaches will not only be applicable for AD, but other neurodegenerative disorders and for delivering other transgenes of interest. ..
  49. PANDAS and Strep Infection: Are they Linked?
    Roger Kurlan; Fiscal Year: 2004
    ..Disproving the PANDAS hypothesis would prevent the use of expensive and potentially dangerous therapies (e.g., plasma exchange, immune globulin, antibiotics) that have been proposed for PANDAS patients. ..
  50. QBP1 Mimetics as Therapeutics for Huntington's Disease
    James Burke; Fiscal Year: 2004
    ..Testing a small number of mimetics for efficacy and toxicity in mouse models of polyglutamine repeat disease will be the subject of a later grant application. ..
  51. Distal Lung Inflammation Effect on Asthma Exacerbations
    Donald Tashkin; Fiscal Year: 2008
    ..This study has the potential to clarify the contribution of the "silent zone" to the persistent morbidity encountered with asthma. ..
  52. Improving memory after hippocampal cell loss
    MARK BARDGETT; Fiscal Year: 2007
    ..The results may shed light on new directions in the treatment of memory disorders, and the proposed work will also enhance education in biomedical research among college undergraduates in Kentucky. [unreadable] [unreadable] [unreadable]..
  53. Metabolic Measures of Tissue Damage
    Robert Bartha; Fiscal Year: 2005
    ..abstract_text> ..
  54. Methylphenidate for Fatigue in Advanced Cancer Patients
    Eduardo Bruera; Fiscal Year: 2009
    ....
  55. RISK MARKERS FOR DEMENTIA AFTER STROKE
    David Nyenhuis; Fiscal Year: 2004
    ..They state that refinement in our knowledge of mechanisms and causes for dementia in stroke patients may lead to an improvement in prevention and treatment strategies. ..
  56. Dementia of Parkinson Type: Clinicopathologic Phenotype
    James Galvin; Fiscal Year: 2004
    ..At the completion of the award period, candidate plans to develop an independent R01 project derived from the data generated by the experiments described in this proposal. ..
  57. Development of Inventory of Depressive Symptomatology
    PUDUGRAMAM DORAISWAMY; Fiscal Year: 2005
    ..g., anxiety, irritability) (IDS-C and SR) that are in the public domain for use with patients across the age spans seen in practice and in research. ..
  58. Brain and Behavior Correlates of Arm Rehabilitation
    Carolee Winstein; Fiscal Year: 2004
    ..abstract_text> ..
  59. Morphine versus Methadone as First Line Strong Opioid for Cancer Pain
    Eduardo Bruera; Fiscal Year: 2009
    ..Relevance to Public Health: In this study, we will test if methadone is better than morphine in cancer pain control, quality of life, and is more cost-effective. ..
  60. Validation of the NINDS VCI Neuropsychology Protocols
    David Nyenhuis; Fiscal Year: 2009
    ..Reliable and valid VCI neuropsychology test protocols are a necessary first step to improved diagnostic criteria and a better understanding of both the mechanisms of VCI and the development of new treatment options. ..
  61. Palliative Oxygen for the Relief of Breathlessness
    Amy Abernethy; Fiscal Year: 2007
    ..The results will also advance a long-standing international debate about the role of palliative oxygen for intractable dyspnea and it's funding. [unreadable] [unreadable] [unreadable]..
  62. Alzheimer's Diagnosis by Real-Time Motion Corrected FMRI
    Clifford Jack; Fiscal Year: 2004
    ..Aim number 4: to assess motion corrected fMRI as a diagnostic test for early Alzheimer's disease. ..